News for Therapeutics Acquisition Corp. (RACA)

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN stock is a Hold.

PR NewswireWILMINGTON, Del., Nov. 18, 2024 Industry veteran with extensive experience in key areas of focusInterim-CFO Richard Narido to focus on HOPE Ther

The markets had a strong week, with the S&P 500 gaining 0.97%. Click here to read more about the portfolio's addition and the game plan for the week ahead.

Numerous drugs under development are projected to come to market later this year and next for Gilead. Read why I rate GILD stock a Buy.

Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based...

Earnings call: Amgen reports robust growth and pipeline progress

Bristol-Myers Squibb expands oncology portfolio with Mirati Therapeutics acquisition

Amgen stock (NASDAQ: AMGN) has seen a 17% rise in a month, outperforming the broader S&P500 index, up 1%.

Amgen appears to remain undervalued for value and income investors. Read more to see a detailed analysis of AMGN stock.

Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year...

January 2023 Developing next-generation immunotherapies that address cancer immune resistance KA Disclaimers and other information Cautionary... | January 5, 2023

Bagsv?, Denmark, 14 October 2022 – Novo Nordisk today announced that the acquisition of Forma Therapeutics Holdings, Inc. , announced on 1 September 2022, has been completed. ... | October 14, 2022

GuruFocus Article or News written by insider and the topic is about:

GuruFocus Article or News written by insider and the topic is about: